GMAB Genmab Earnings and EPS analysis

EPS in 2026 (TTM): $1.28

Last Report Period Date: Jun 30, 2026

Based on the company's latest reports for June 2026, the current 12-month EPS is $1.28. Genmab's earnings per share in 2025 was reported at $1.55, marking a decline from $1.77 in 2024. In the quarterly report ending on Jun 30, 2026, GMAB's earnings per share amounted to $0.49.

Genmab had an yealy earnings per share of $1.55, showing a decline of 12.4% from $1.77 recorded in 2024. The quarterly earnings per share for the period ending Jun 30, 2026, was $0.49, showing a 9.3% decline compared to the same quarter last year. The trailing twelve months EPS for GMAB is $1.28 as of June 2026. Genmab's full-year EPS for 2024 was $1.77, a 82.5% rise compared to the previous year.

Genmab has recorded a decline in earnings per share of 9.3% in the past 12 months (YoY, quarterly). Over an extended period, the company registered an average EPS annual growth rate of 10.5% per year during the last 3 years. Genmab had an average annual EPS growth of 8.7% in the last five years.